Description : Each tablet contains telmisartan 40 or 80 mg and hydrochlorothiazide 12.5 mg.
Telmisartan is [1,1′-biphenyl]-2-carboxylic acid,4′-[(1,4′-dimethyl-2′-propyl[2,6-bi-1H-benzimidazole]-1′-yl)methyl].
Indications / Uses : Treatment of essential HTN for patients in whom combination therapy is appropriate.
Administration : May be taken with or without food.
Contraindications : Cholestasis & biliary obstructive disorders. Severe hepatic & renal impairment (CrCl <30 mL/min). Refractory hypokalemia, hypercalcemia. Concomitant use of aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). Pregnancy & lactation.
Special Precautions : Impaired hepatic function or progressive liver disease. Bilateral or unilateral renal artery stenosis, renal impairment, recent kidney transplant. Vol &/or Na depletion. Severe CHF or underlying renal disease. Primary aldosteronism. Aortic or mitral valve stenosis, obstructive cardiomyopathy. DM, hereditary fructose & galactose intolerance, ischemic cardiopathy or CV disease, history of allergy or bronchial asthma, SLE. Idiosyncratic reaction resulting in acute transient myopia & acute angle-closure glaucoma.